NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Decheng Capital LLC

Decheng Capital LLC lessened its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 45.1% during the 1st quarter, HoldingsChannel reports. The firm owned 325,057 shares of the company’s stock after selling 267,000 shares during the quarter. NewAmsterdam Pharma accounts for about 1.6% of Decheng Capital LLC’s investment portfolio, making the stock its 7th biggest holding. Decheng Capital LLC’s holdings in NewAmsterdam Pharma were worth $10,405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock valued at $594,388,000 after purchasing an additional 241,818 shares in the last quarter. Capital World Investors boosted its holdings in NewAmsterdam Pharma by 1.6% during the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after buying an additional 161,289 shares in the last quarter. Wellington Management Group LLP boosted its holdings in NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc grew its position in NewAmsterdam Pharma by 15.6% during the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after buying an additional 393,855 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, BMO Capital Markets began coverage on NewAmsterdam Pharma in a report on Monday. They issued an “outperform” rating and a $58.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.42.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $869,158.57. The trade was a 72.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $31.70 on Thursday. The company’s fifty day moving average price is $33.05 and its 200 day moving average price is $32.92. NewAmsterdam Pharma Company N.V. has a 1 year low of $21.14 and a 1 year high of $42.21. The stock has a market capitalization of $3.71 billion, a P/E ratio of -17.71 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. Sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.